Skip to Content

Xiao Ni, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Dermatology - Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Faculty, The University of Texas, Graduate School of Biomedical Sciences, Houston, TX

Bio Statement

Have leaded a preclinical study about dendritic cell vaccine on cutaneous T-cell lymphoma (CTCL). By finishing this project, we established the optimal protocol for further clinical study, and we also established a collaborative team of basic immunologists, physician scientists, and clinicians.

Have three ongoing research projects:

One project is implementing to the clinical trial of anti-CCR4 antibody on CTCL. We are assessing the effect of this antibody on regulatory T cells, an immune suppressive cell, if the antibody could reduce or eliminate the Treg, it could be used for many tumors which have increased Tregs.

Another project is to identify the biomarkers for response and resistance to photopheresis for CTCL, and hope that we could find a set of signature genes to help us subgroup patients for better specific therapy indications.

The new project is to find molecular genetic mutations contributing to CTCL and further determine the effect of tumor-associated molecular markers on overall survival, progression free survival and response to targeted therapy.

Research Interests

Skin immunology, tumor immunology, immunotherapy, dendritic cell subsets, and T cell subsets

Education & Training

Degree-Granting Education

1999 Peking Union Medical College, Beijing, China, PHD, Investigative Dermatology
1983 Nantong Medical College, Nantong, China, MD, Medicine

Postgraduate Training

2/2000-12/2003 Postdoctoral Fellow, tumor immunology, immunotherapy, Cutaenous T-cell Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX
1988-1989 Clinical Fellowship, Dermatopathology, Institution of Dermatology, The Chinese Academy of Medicine and Sciences, Nanjing, China
1984-1988 Clinical Residency, Dermatology, University of Nanjing - Affiliated Gulou Hospital, Nanjing, Jiangsu, China


Institutional Committee Activities

Member, The Clinical Research Committee, 9/2008-8/2010

Professional Memberships

American Society of Hematology
Member, 2007-present
The American Association for the Advancement of Science
Member, 2002-2012
The Society of Investigative Dermatology
Member, 2002-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. J Cutan Pathol 39(5):500-7, 5/2012. PMID: 22515221.
2. Shiue LH, Ni X, Prieto VG, Jorgensen JL, Curry JL, Goswami M, Sweeney SA, Duvic M. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol 18. e-Pub 1/2012. PMID: 22257096.
3. Ni X, Richmond H, Liao X, Decker W, Shiue L, Shpall E, Duvic M.. Induction of T-cell Responses against Cutaneous T-cell Lymphomas ex vivo by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. J Invest Dermatol 128(11):2631-2639, 11/2008. e-Pub 5/2008. PMID: 18480841.
4. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1):31-9, 1/1/2007. PMID: 16960145.
5. Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, Duvic M. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions. Arch Dermatol Res 298(7):353-6, 12/2006. PMID: 17021762.
6. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 124(4):741-750, 2005. PMID: 15816832.
7. Zhang CL, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125(5):1045-52, 2005. PMID: 16297208.
8. Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol 123(2):380-7, 8/2004. PMID: 15245439.
9. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% Gel for Refractory Mycosis Fungoides Lesions: An Open-label Pilot Study. J Am Acad Dermatol 50(5):600-607, 2004. PMID: 15034511.
10. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Joseph A, Hazarika P. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 121(4):902-9, 10/2003. PMID: 14632211.
11. Zhang CL, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of therapeutic Action. Clin Cancer Res 8(5):1234-1240, 2002. PMID: 12006543.
12. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T- lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? . Clin Cancer Res 7(9):2682-92, 9/2001. PMID: 11555580.
13. Ni X, Sun JF. Methygreen-Pyronin staining for apoptotic cells in psoriatic Lesions. Journal of Clinical Dermatology 29(6):334-336, 2000.
14. Ni X, Sun JF, Zeng XS,Sang HG, Li AM, Ye GY. The excessive prolifereation and apoptosis are correlated with the abnormal expression of c-myc, P53 and bcl-2 in psoriatic lesions. Chinese Journal of Dermatology 33(4):240-242, 2000.
15. Ni X, Sun JF. The value of pathological examinaton in the diagnosis of atypical psoriasis. Chinese Journal of Dermatology and Venereology 13(2):75-76, 1999.
16. Ni X, Jiang YQ, Sun JF. Apoptosis and Pilomatricoma. Chinese Journal of Dermatology 31(6):386-387, 1998.
17. Ni X, Yang HP, Sun JF. Excessive proliferation and apoptosis in both keratinocytes and infiltrating lymphocytes of psoriatic lesions. Chinese Journal of Dermatology 31(2):95-96, 1998.
18. Yang HP, Ni X, Sun JF. Psoriasis arthropathica: analysis of 26 cases. Chinese Journal of Dermatology 31(2):114- 115, 1998.
19. Ni X. A case study: Piebaldism and the pedigree analysis. Journal of Clinical Dermatology 24(1):50, 1995.
20. Ni X, Chen ZG, Zhu WW. Epidermal-grafting for the patient with piebaldism. Chinese Journal of Dermatology 28(4):261, 1995.
21. Ni X, Fang Y, Zhu WW. A clinical trial of Germanium Huangqi for psoriasis vulgaris. Chinese Journal of Dermatology 27(6):377-378, 1994.
22. Ni X, Lu ML, Li FQ. Clinical efficacy of chinese herbs for summer dermatitis. Journal of Clinical Dermatology 23(1):46, 1994.
23. Ni X. Two cases of anhidrotic ectodermal dysplasia. Chinese Journal of Dermatology 27(3):183, 1994.
24. Ni X, Li FQ. Analysis of non-papillomatous hyperplastic lesions in genitalia. Jiangsu Medical Journal 19:282, 1993.
25. Gu JG, Gu XJ, Ni X. Clinical efficacy of enoxacin for skin infectious dieseases. Chinese Journal of Antibiotics 18(6):465-468, 1993.
26. Ni X, Li FQ. A case study: pseudo-acanthosis nigricans. Chinese Journal of Dermatology 25(5):348, 1992.
27. Ni X, Li FQ, Liu JH. A case study: cutaneous T cell lymphoma manifesting lethal midline granuloma. Chinese Journal of Dermatology 24(4):275-276, 1991.

Invited Articles

1. Ni X, Duvic M. Dendritic cells and Cutaneous T-cell Lymphomas. G Ital Dermatol Venereol 146(2):103-13, 4/2011. PMID: 21505396.
2. Ni X, Sun JF. In situ polymerase chain reaction and its applications in the dermatology. Foreign Medical Sciences 23(5):279-282, 1997.
3. Ni X, Sun JF. Updates of the molecular biological studies on psoriasis. Foreign Medical Sciences 23(2):85-87, 1997.


1. Ni X, Jorgensen J, Goswami M, Challagundla P, Decker W, Kim Y, Duvic M. Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma. Blood 118(21):444, 11/2011.
2. LH Shiue, M Goswami, A Alousi, C Hosing, M Duvic, X Ni. Effect of extracorporeal photopheresis on dendritic cell populations in patients with Sézary syndrome and graft versus host disease. Journal of Investigative Dermatology 130(S1):S119, 4/2010.
3. Ni X, Goswami M, Shiue LH, Dougherty A , and Duvic M. Increased Twist expression in advanced stage of CTCL. Journal of Investigative Dermatology 130(S1), 4/2010.
4. LH Shiue, E Ahkus, P Arias-Mendoza, M Duvic, X Ni. Increased levels of CD4+25high regulatory T cells in patients with cutaneous T-cell lymphoma after extracorporeal photopheresis. Journal of Investigative Dermatology 129(S1):S46, 4/2009.
5. Dougherty A, Shiue L, Bassett R, Duvic M , Prieto V, and Ni X. Increased Syndecan-4 expression in malignant T -lymphocytes is associated with progression in Mycosis Fungoides. Journal of Investigative Dermatology 129(S1):S45, 4/2009.
6. Ni X, Shiue L, Arias-Mendoza P, Aakhus E, Hosing C, and Duvic M. Foxp3 Expression is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extrocorporeal Photopheresis. Blood 112::2912, 11/2008.
7. Ni X,Zhou WH,Shiue L, Aakhus E, Duvic M. A novel approach to study tumor-specific CD8+ cytotoxic T lymphocyte in cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. J Invest Dermatol 129, 2008.
8. Ni X, Kelly C, Talpur R, Zhang C, Breuer-Mc-Ham J, Richon V, Duvic M. Anti-angiogenic effect of vorinostar (suberoylanilide hydroxamic acid, SAHA), a histone deacetylase inhibitor, in CTCL lesions. J Invest Dermatol. 126:2, 2006.
9. Ni X, Liao XS, Segall H, Zhang CL, Shpall E, Duvic M. Apoptotic cells and tumor cell lysate pulsed CD14+monocyte-derived dendritic cells from cutaneous T-cell lymphoma mature and induce allogenic T-cell proliferation in vitro. J Invest Dermatol 122(3):A121, 2004.
10. Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Hazarika P, Josephs A, Duvic M. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and upregulated by tazarotene in vivo. J Invest Dermatol 121(1):191, 2003.
11. Ni X, Zhang CL, Hazarika P, Duvic M. Functional Fas ligand is expressed in human cutaneous T cell lymphoma cells and inhibited by Bexarotene. J Invest Dermatol 119(1):217, 2002.
12. Hazarika P, Geoge S, Prieto V, Ni X, Bar-Eli MM, Duvic M. Over-expression of a novel caveolae associated protein, Flotillin-2, is associated with melanoma progression. J Invest Dermatol 119(1):223, 2002.
13. Ni X, Zhang CL, Hazarika P, Duvic M. Fas/Fas ligand-mediated elimination of cytotoxic CD8+ lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. J Invest Dermatol 117(2):490, 2001.

Book Chapters

1. Ni X. Dermatopathology - Introduction. In: The Basis of Modern Dermatology. the People's Medical Publishing House, 1035-1063, 2001.
2. Ni X, Sun J, Liu J. History of Dermatopathology in China. In: Chinese Modern Scientific Encyclopedia. Scientific Publishing House, 2000.
3. Ni X. Benign and Malignant epidermal tumors. In: Atlas of Dermatology and Venereology. the People's Medical Publishing House, 337-354, 1998.

Grant & Contract Support

Title: Identifying biomarkers of response and resistance to ECP in patients with MF/SS
Funding Source: Therakos,Inc.
Role: Principal Investigator
Duration: 11/1/2010 - 4/30/2014
Title: The role of Twist in tumor transformation and progression of Mycosis Fungoides (MF)/Sézary Syndrome (SS)
Funding Source: Dermatology Foundation
Role: Principal Investigator
Duration: 7/1/2010
Title: The role of Twist in tumor transformation and progression of Mycosis Fungoides (MF)/Sézary Syndrome (SS)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 2/1/2010
Title: A Randomized Phase II Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination with Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease (GVHD)
Funding Source: Therakos,Inc.
Role: Collaborator
Principal Investigator: Amin Alousi
Duration: 10/8/2009 - 10/31/2014
Title: Induction of Polyclonal T-cell Responses against Cutaneous T-cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA
Funding Source: Ladies Leukemia League
Role: Principal Investigator
Duration: 6/1/2005 - 5/31/2007
Title: Strategies for effective ex vivo priming of cutaneous T-cell lymphoma -specific cytotoxic T lymphocytes by autologous dendritic cells pulsed with whole tumor cells
Funding Source: Dermatology Foundation
Role: Principal Investigator
Duration: 8/1/2003 - 7/31/2005

Last updated: 3/12/2013